Review Article
Flavonoids Targeting the mTOR Signaling Cascades in Cancer: A Potential Crosstalk in Anti-Breast Cancer Therapy
Table 1
mTOR inhibitors used in clinical trials for the management of different breast cancers.
| Drugs/compounds | Study design | Nature of breast cancer | References |
| Fulvestrant+everolimus | Phase II clinical trials | Positive breast cancer (estrogen receptor) | [31] | Everolimus | Retrospective | Metastatic breast cancer | [32] | Exemestane+everolimus | Phase III (randomized trial) | Advanced breast cancer (hormone-receptor-positive) | [33] | Temsirolimus | Phase II | Metastatic breast cancer | [34] | Tamoxifen+everolimus | Phase II (randomized trial) | Metastatic breast cancer | [35] | Tamoxifen+sirolimus | Phase I and phase II | HER2-negative breast cancer and hormone receptor-positive | [36] | Plustrastuzumab+vinorelbine+everolimus | Phase III | HER2-positive breast cancer | [37] | Trastuzumab+ridaforolimus | Phase IIb | Trastuzumab-refractory metastatic breast cancer (human epidermal growth factor receptor 2–positive) | [38] | Paclitaxel+trastuzumab+everolimus | Phase II | Advanced breast cancer (HER-2 positive) | [39] | Letrozole+temsirolimus | Phase III randomized | Metastatic breast cancer (hormone receptor-positive) | [40] |
|
|